• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Advertisement

Hyderabad Feb. 22 In a single stroke, the Hyderabad-based Aurobindo Pharma Ltd has obtained registrations for nine of its anti-retrovirals (ARVs) from Botswana. The company announced that the DRU (drugs regulatory unit) of Botswana has registered Lamivudine and Zidovudine tablet, Zidovudine oral solution 50 mg/5 ml, Nevirapine oral suspension 50 mg/ml, Lamivudine oral solution 10 mg/ml, Nevirapine 200 mg tablet, Stavudine 30 mg capsules, Stavudine 40 mg capsules, Lamivudine 150 mg tablets, and Lamivudine 300 mg tablets. The products are used extensively in the management of HIV positive patients.

More Stories on : Announcements | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Evolvence India to invest $10 m in Bangalore co

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line